Navigation Links
Study Shows Increases in Working After 65 and Using Commercial Insurance
Date:6/17/2009

MINNEAPOLIS, June 17 /PRNewswire/ -- Deft Research recently released the 2009 Age-In Study, which describes the expectations of those aged 63-64 for their retirement and health insurance. The study also develops a picture of health insurance preferences and priorities among persons in this group. This group is known as "age-ins" by health insurers because at 65 they become eligible for Medicare benefits and so must make their first decision about Medicare related health insurance.

According to the study, among those who have decided to work or retire, the percentage of age-ins who will continue working after age 65 has increased in the past year from 43% to 55%. And among those who will continue working, the largest share will look to commercial employee health benefits as their primary source of health insurance. Overall, 48% of all age-ins will purchase individual Medicare coverage from a Medicare Advantage plan or a Medigap carrier after they turn 65. For health insurers, this means that as more people in their mid-60's stay in the workforce, the consumer market that needs a Medicare plan at 65 is diminishing. The competition therefore is to be most effective at marketing to a diverse group who will retire along a range of ages.

The study helps by identifying market segments based on retirement approaches as well as different health benefit preferences for each segment. "Both market segments and preferences can be tied together," said Rich Hamer, Principal at Deft Research, "the study results could be used by plans to target segments with a specific message and product offer best suited for them."

The study was conducted in May of 2009 and included 1,469 age-in participants. The study linked its primary research to Nielsen Claritas' PRIZM to better understand who and where the best customers for specific types of Medicare related plans are. Recipients of the report will also have the opportunity fo
'/>"/>

SOURCE Deft Research, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
2. AGH Joins Select Group of Medical Centers in Study of Promising New Technology for Treatment of Heart Failure
3. Study Refutes Depression Gene Finding
4. Providing health insurance for US children would be cheaper than expected, study says
5. Study finds autistics better at problem-solving
6. Cannabis alters human DNA -- new study
7. HPV Vaccine Acceptability Study Announces Results
8. MUHC researcher awarded $500,000 to study pathogenesis of infectious disease
9. HealthLeaders-InterStudy Launches Pharmacy Benefit Evaluator
10. Scientific Study Makes it Possible to Measure Connection Between People
11. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3